Clicky

Harmony Biosciences Holdings, Inc.(HRMY)

Description: Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients living with rare neurological disorders. Its lead product includes WAKIX (pitolisant) for the treatment of pediatric patients suffering from narcolepsy. Harmony Biosciences Holdings, Inc. was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. The company was founded in 2017 and is based in Plymouth Meeting, Pennsylvania.


Keywords: Pharmaceutical Neurological Disorders Chloroarenes Ethers Stage Pharmaceutical Urological Disorders Functional Groups Piperidines Narcolepsy Stimulants Rare Neurological Disorders

Home Page: www.harmonybiosciences.com

HRMY Technical Analysis

630 West Germantown Pike
Plymouth Meeting, PA 19462
United States
Phone: 484 539 9800


Officers

Name Title
Mr. Jeffrey S. Aronin Founder & Non-Exec. Chairman
Mr. John Charles Jacobs M.B.A. Pres, CEO & Director
Mr. Sandip S. Kapadia CPA, M.B.A. Exec. VP & CFO
Dr. Jeffrey M. Dayno M.D. Exec. VP & Chief Medical Officer
Mr. Jeffrey Dierks M.B.A. Exec. VP & Chief Commercial Officer
Mr. Andrew Serafin J.D., M.B.A. Exec. VP & Chief Strategy Officer
Mr. David Bradshaw Head of Technical Operations
Ms. Sharon Goldbach Head of Facilities Operations & Exec. Admin.
Luis Sanay Head of Investor Relations
Mr. Christian Ulrich Gen. Counsel

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 25.641
Trailing PE: 18.7144
Price-to-Book MRQ: 10.1167
Price-to-Sales TTM: 8.308
IPO Date: 2020-08-19
Fiscal Year End: December
Full Time Employees: 180
Back to stocks